Type 1 innate lymphoid cells are associated with type 2 diabetes

Area of Science:

• Immunology
• Endocrinology
• Metabolic Diseases

Background:

• Type 1 innate lymphoid cells (ILC1s) are crucial regulators of systemic inflammation.
• The specific role of ILC1s in the pathogenesis of type 2 diabetes (T2D) is not well understood.
• Investigating ILC1s in T2D could reveal novel insights into glucose homeostasis and diabetes development.

Purpose of the Study:

• To investigate the relationship between ILC1s and glucose homeostasis in humans.
• To determine if ILC1 levels differ between individuals with and without T2D.
• To explore the association of ILC1s with key metabolic parameters in T2D.

Main Methods:

• Comparative analysis of ILC1 populations in peripheral blood mononuclear cells (PBMCs) and omental adipose tissue.
• Inclusion of 37 newly diagnosed T2D patients and 32 normal glucose tolerance (NGT) subjects, matched for age and BMI.
• Flow cytometric analysis to quantify ILC1 numbers and frequencies.

Main Results:

• T2D patients exhibited significantly higher circulating and adipose tissue ILC1 levels compared to NGT subjects (P < 0.05).
• ILC1 levels positively correlated with HbA1c, FPG, HOMA-IR, Adipo-IR, and FFAs.
• Higher ILC1 levels were associated with a 13.481-fold increased risk of developing T2D.

Conclusions:

• This study provides the first evidence linking ILC1 abnormalities to diabetes development.
• Altered ILC1 populations are implicated in the pathogenesis of T2D.
• ILC1s represent a potential biomarker for therapeutic intervention in T2D management.